| iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics L Seymour, J Bogaerts, A Perrone, R Ford, LH Schwartz, S Mandrekar, ... The Lancet Oncology 18 (3), e143-e152, 2017 | 2225 | 2017 |
| RECIST 1.1—Update and clarification: From the RECIST committee LH Schwartz, S Litière, E De Vries, R Ford, S Gwyther, S Mandrekar, ... European journal of cancer 62, 132-137, 2016 | 1737 | 2016 |
| Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases PW Sperduto, N Kased, D Roberge, Z Xu, R Shanley, X Luo, PK Sneed, ... Journal of Clinical Oncology 30 (4), 419-425, 2012 | 1557 | 2012 |
| 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, MS Aapro, F André, ... Annals of Oncology 31 (12), 1623-1649, 2020 | 1245 | 2020 |
| Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer RK Murthy, S Loi, A Okines, E Paplomata, E Hamilton, SA Hurvitz, NU Lin, ... New England Journal of Medicine 382 (7), 597-609, 2020 | 1231 | 2020 |
| Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment AC Garrido-Castro, NU Lin, K Polyak Cancer discovery 9 (2), 176-198, 2019 | 1159 | 2019 |
| Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets PK Brastianos, SL Carter, S Santagata, DP Cahill, A Taylor-Weiner, ... Cancer discovery 5 (11), 1164-1177, 2015 | 1090 | 2015 |
| Response assessment criteria for brain metastases: proposal from the RANO group NU Lin, EQ Lee, H Aoyama, IJ Barani, DP Barboriak, BG Baumert, ... The lancet oncology 16 (6), e270-e278, 2015 | 982 | 2015 |
| Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors VA Adalsteinsson, G Ha, SS Freeman, AD Choudhury, DG Stover, ... Nature communications 8 (1), 1324, 2017 | 920 | 2017 |
| CNS metastases in breast cancer NU Lin, JR Bellon, EP Winer Journal of clinical oncology 22 (17), 3608-3617, 2004 | 917 | 2004 |
| Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer: high incidence of central nervous system metastases NU Lin, E Claus, J Sohl, AR Razzak, A Arnaout, EP Winer Cancer 113 (10), 2638-2645, 2008 | 881 | 2008 |
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ... Clinical cancer research 15 (4), 1452-1459, 2009 | 773 | 2009 |
| Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study DN Cagney, AM Martin, PJ Catalano, AJ Redig, NU Lin, EQ Lee, PY Wen, ... Neuro-oncology 19 (11), 1511-1521, 2017 | 745 | 2017 |
| Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network NU Lin, A Vanderplas, ME Hughes, RL Theriault, SB Edge, YN Wong, ... Cancer 118 (22), 5463-5472, 2012 | 738 | 2012 |
| 21-gene assay to inform chemotherapy benefit in node-positive breast cancer K Kalinsky, WE Barlow, JR Gralow, F Meric-Bernstam, KS Albain, ... New England Journal of Medicine 385 (25), 2336-2347, 2021 | 641 | 2021 |
| Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer N Tung, NU Lin, J Kidd, BA Allen, N Singh, RJ Wenstrup, AR Hartman, ... Journal of Clinical Oncology 34 (13), 1460-1468, 2016 | 576 | 2016 |
| Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2–positive breast cancer NU Lin, LA Carey, MC Liu, J Younger, SE Come, M Ewend, GJ Harris, ... Journal of clinical oncology 26 (12), 1993-1999, 2008 | 547 | 2008 |
| Cyclin D1 stimulation of estrogen receptor transcriptional activity independent of cdk4 E Neuman, MH Ladha, N Lin, TM Upton, SJ Miller, J DiRenzo, RG Pestell, ... Molecular and cellular biology 17 (9), 5338-5347, 1997 | 503 | 1997 |
| Brain metastases: the HER2 paradigm NU Lin, EP Winer Clinical Cancer Research 13 (6), 1648-1655, 2007 | 497 | 2007 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 480 | 2020 |
Nikhil WagleDana-Farber Cancer Institute, Harvard Medical School / Broad Institute of MIT and HarvardE-mail megerősítve itt: dfci.harvard.edu
